tiprankstipranks
Trending News
More News >
Qyuns Therapeutics Co., Ltd. Class H (HK:2509)
:2509
Hong Kong Market
Advertisement

Qyuns Therapeutics Co., Ltd. Class H (2509) Stock Statistics & Valuation Metrics

Compare
0 Followers

Total Valuation

Qyuns Therapeutics Co., Ltd. Class H has a market cap or net worth of ―. The enterprise value is HK$1.60B.
Market Cap
Enterprise ValueHK$1.60B

Share Statistics

Qyuns Therapeutics Co., Ltd. Class H has 222,071,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding222,071,600
Owned by Insiders
Owned by Institutions

Financial Efficiency

Qyuns Therapeutics Co., Ltd. Class H’s return on equity (ROE) is -1.47 and return on invested capital (ROIC) is -42.63%.
Return on Equity (ROE)-1.47
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-42.63%
Return on Capital Employed (ROCE)-0.59
Revenue Per Employee468.42K
Profits Per Employee-989.89K
Employee Count339
Asset Turnover0.16
Inventory Turnover19.96

Valuation Ratios

The current PE Ratio of Qyuns Therapeutics Co., Ltd. Class H is ―. Qyuns Therapeutics Co., Ltd. Class H’s PEG ratio is ―.
PE Ratio
PS Ratio0.00
PB Ratio0.00
Price to Fair Value6.64
Price to FCF0.00
Price to Operating Cash Flow-16.32
PEG Ratio

Income Statement

In the last 12 months, Qyuns Therapeutics Co., Ltd. Class H had revenue of 158.79M and earned -335.57M in profits. Earnings per share was -1.53.
Revenue158.79M
Gross Profit92.19M
Operating Income-326.37M
Pretax Income-349.76M
Net Income-335.57M
EBITDA-311.82M
Earnings Per Share (EPS)-1.53

Cash Flow

In the last 12 months, operating cash flow was -186.09M and capital expenditures 0.00, giving a free cash flow of -186.09M billion.
Operating Cash Flow-186.09M
Free Cash Flow-186.09M
Free Cash Flow per Share-0.84

Dividends & Yields

Qyuns Therapeutics Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.44
52-Week Price Change-8.87%
50-Day Moving Average16.11
200-Day Moving Average11.23
Relative Strength Index (RSI)65.81
Average Volume (3m)424.88K

Important Dates

Qyuns Therapeutics Co., Ltd. Class H upcoming earnings date is Aug 15, 2025, Before Open (Confirmed).
Last Earnings DateMar 28, 2025
Next Earnings DateAug 15, 2025
Ex-Dividend Date

Financial Position

Qyuns Therapeutics Co., Ltd. Class H as a current ratio of 1.43, with Debt / Equity ratio of 230.41%
Current Ratio1.43
Quick Ratio1.43
Debt to Market Cap0.35
Net Debt to EBITDA-0.54
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Qyuns Therapeutics Co., Ltd. Class H has paid 73.00K in taxes.
Income Tax73.00K
Effective Tax Rate>-0.01

Enterprise Valuation

Qyuns Therapeutics Co., Ltd. Class H EV to EBITDA ratio is -5.41, with an EV/FCF ratio of -9.07.
EV to Sales10.63
EV to EBITDA-5.41
EV to Free Cash Flow-9.07
EV to Operating Cash Flow-9.07

Balance Sheet

Qyuns Therapeutics Co., Ltd. Class H has HK$556.55M in cash and marketable securities with HK$527.60M in debt, giving a net cash position of -HK$28.96M billion.
Cash & Marketable SecuritiesHK$556.55M
Total DebtHK$527.60M
Net Cash-HK$28.96M
Net Cash Per Share-HK$0.13
Tangible Book Value Per ShareHK$0.99

Margins

Gross margin is 58.06%, with operating margin of -205.53%, and net profit margin of -211.33%.
Gross Margin58.06%
Operating Margin-205.53%
Pretax Margin-220.26%
Net Profit Margin-211.33%
EBITDA Margin-196.37%
EBIT Margin-215.56%

Analyst Forecast

The average price target for Qyuns Therapeutics Co., Ltd. Class H is HK$15.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$15.00
Price Target Upside-27.33% Downside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart ScoreN/A
AI Score55
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis